SYK - Stryker Corporation
| Previous Close | 200.49 |
| Open | 202.53 |
| Bid | 202.42 x 1200 |
| Ask | 202.59 x 800 |
| Day's Range | 201.89 - 204.11 |
| 52 Week Range | 144.75 - 204.11 |
| Volume | 323,520 |
| Avg. Volume | 1,157,978 |
| Market Cap | 75.591B |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | 21.85 |
| EPS (TTM) | 9.27 |
| Earnings Date | Jul 22, 2019 - Jul 26, 2019 |
| Forward Dividend & Yield | 2.08 (1.04%) |
| Ex-Dividend Date | 2019-06-27 |
| 1y Target Est | 200.15 |
- Zacks•yesterday
Here's Why You Should Hold on to Stryker (SYK) Stock Now
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
- Motley Fool•yesterday
These Are the Top CEOs (According to Employees)
The top performers have at least a 99% approval rate.
- Simply Wall St.•3 days ago
Why Dividend Hunters Love Stryker Corporation (NYSE:SYK)
Could Stryker Corporation (NYSE:SYK) be an attractive dividend share to own for the long haul? Investors are often...
- Zacks•8 days ago
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
- Zacks•9 days ago
Top Stock Reports for Intel, Altria & Stryker
Top Stock Reports for Intel, Altria & Stryker
- Insider Monkey•9 days ago
Is Stryker Corporation (SYK) A Good Stock To Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Stryker Corporation (NYSE:SYK). Is Stryker Corporation (NYSE:SYK) the right pick […]
- Zacks•10 days ago
What's in the Offing for HEXO Corp's (HEXO) Q3 Earnings?
HEXO Corp's (HEXO) recent 1,000,000 sq. ft. greenhouse expansion is likely to reflect on quarterly results.
- Markit•10 days ago
See what the IHS Markit Score report has to say about Stryker Corp.
Stryker Corp NYSE:SYKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for SYK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting SYK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SYK totaled $4.16 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- InvestorPlace•14 days ago
5 Healthcare Stocks to Pick Up From the Wreckage
Once loved, healthcare stocks are quickly becoming some of the most hated stocks on the planet. It's easy to understand why. Rising drug and procedure costs have made many healthcare stocks targets for various political pundits and presidential candidates. The growing calls for Medicare-For-All and/or socialized medicine has the potential to hit many healthcare firms right in the pocket. When coupled with the general market sell-off, the fast-moving healthcare sector has been a real downer.But that has only made the sector prime for bargain shopping.Even with calls for increased regulation, the healthcare sector still has great long-term potential. Thanks to rising global demand, aging populations as well as new high-tech and high-margined therapies, there are lots of levers for the sector to pull in order to keep the profits coming. And while some healthcare stocks will be hit hard in the regulation wave (like insurance and pharmacy benefit managers), many will be just fine. This could make the recent declines a tantalizing buy-in point for portfolios.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets With the long-term in mind, here are five healthcare stocks that are worth picking up from the wreckage. Abiomed (ABMD)Source: Shutterstock There's a good chance that you've never heard of Abiomed (NASDAQ:ABMD). The firm was only added to the S&P 500 about a year ago. But in that time, it has grown immensely in terms of fundamentals and share price.ABMD produces the Impella, which is the world's smallest heart pump. The device is minimally invasive. That's a key selling point for doctors. Open-heart surgery is risky to begin with, but especially so for patients who have suffered some sort of major cardiovascular event. Impella eliminates many of the risks. Meanwhile, the device can be configured in a variety of applications. Because of this, the Impella is quickly becoming the standard of care for doctors in cardiac surgery.As a result, sales of the device continue to surge. For full-year 2018 results, ABMD managed to see a 30% jump in sales and nearly 43% increase in profits based on continued demand for the game-changing device. And yet, the runway is still long for the firm. There's plenty of market share in the U.S. to gain from older heart pump devices and global demand is still in its infancy. Meanwhile, the firm continues to attract plenty of buyout/M&A buzz and would be a wonderful tuck-in deal for many larger device stocks.However, shares of ABMD are about 35% below their all-time highs from last year. And it isn't cheap from a price-to-earnings perspective either. ABMD is a classic growth stock, but the recent dip makes for an interesting buy-in for those willing to hold it over the long term. Teledoc (TDOC)Source: MayApps207 via WikiMedia Saving money and reducing costs is exactly what any pending regulation in the sector will be all about. That's great news for Teledoc (NASDAQ:TDOC). The firm is the largest player in the growing telemedicine field. Here, patients can fire-up their tablets, PCs or smartphones and speak to a physician in real time, get a diagnosis and even send a prescription to their local pharmacy.Health insurers, benefit managers, employers and consumers seem keen on the idea. More employers are adding the service to their benefits package, with more than 40% of the Fortune 500 offering it in their benefits.This has allowed TDOC to experience some very fast growth over the last few years. between 2016 and what its estimated to pull in this year, Teledoc has seen a staggering 64% compound annual growth rate in terms of revenues. Meanwhile, the firm is finally starting to turn those revenues into meaningful and growing profits.And the growth could continue. TDOC has moved into the mental health arena and has been smartly buying smaller rivals to add instant market share. Meanwhile, more companies continue to see the benefits of adding the platform to their Human Resources package. * The 10 Best Stocks for 2019 -- So Far All in all, TDOC is a high growth healthcare stock that is now trading much lower than expected. Amgen (AMGN)Source: Shutterstock As one of biotech and healthcare's elder statesmen, Amgen (NASDAQ:AMGN) has been hit hard over the last year on drug pricing news. Key blockbusters like Enbrel and Neulasta are two of the most prescribed drugs in their categories and mint cash for AMGN. Those blockbusters, as well as others, such as Repatha, blood-cancer drug Kyprolis and bone-density drug Prolia, are the reasons why Amgen has become a dividend and buyback stalwart. Their high prices are also the reason why AMGN is in the crosshairs of lawmakers.Despite that and the drop in AMGN stock, investors may want to consider the firm.For one thing, Amgen continues to dive head first into more advanced cancer and gene therapy drugs. These specialized drugs are naturally higher cost. There's very little that regulation can do for them. With data from Amgen's new cancer therapies crushing the trial, there's a good chance that the firm will have another blockbuster in its arsenal. And we can't forget about its massive pipeline either.In the end, AMGN will be pretty immune from the effects of regulation and will continue to rack up massive cash flows from specialized drugs. That should help pad its now 3.32% dividend for years to come. Stryker Corporation (SYK)Source: Shutterstock Artificial knees, hospital beds and even specialized bone cement … medical device company Stryker (NYSE:SYK) has it all. And that could make it a top healthcare stock contender to snag-up in the recent sector wreckage. SYK has its hands in many pots and that will allow it to handle anything the government throws at it.This is evident by its continued surge in sales and revenues. Last quarter, SYK managed to see a big 8.5% jump in net sales. The key was that divisions featuring more high-tech devices and products, such as orthopedics and neurotechnology, saw big double-digit sales gains. The medical device firm has continued to boost these divisions with smart M&A as well as new innovative internal product launches. That's a good thing as these higher-tech areas are seen as being more insulated to regulation. For Stryker and its shareholders, this could be gold for the long haul.Speaking of that gold, SYK has been sharing the wealth with investors as well. The firm's latest dividend represents a big 11% increase. At the same time, Stryker has been a buyback champ as well -- reducing its share count by about $1 billion last year. * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right With a forward P/E of 22, Stryker isn't super cheap, but considering its growth estimates and potential to keep the good times going in the face of regulation, that could seem like a bargain. Bristol-Myers Squibb (BMY)Source: A 4 via Flickr It's not surprising that old-school pharma has been hit hard in recent weeks. But there's nothing particularly old school about Bristol-Myers Squibb (NYSE:BMY). That's because BMY has quickly become the anti-cancer and advanced drug machine.BMY already had top blockbuster cancer-fighter Opdivo, which pulls in more than $2 billion in quarterly revenues for the firm. But thanks to its recent $74 billion out of Celgene (NASDAQ:CELG), Bristol-Meyers will have one of the richest oncology portfolios around. This includes blockbusters Yervoy, Revlimid and Pomalyst which will all now be under its umbrella. This doesn't even include CELG's rich pipeline nor BMY's own advanced cancer-fighting drugs under development.As we said before, specialized cancer drugs are big revenues drivers and given just how advanced they are, the government may have little ability to regulate them. This should help drive revenues and cash flows at Bristol-Meyer's for years to come. And yes, patent expiration for Revlimid is coming down the pike. But under BMY's vast portfolio of drugs, that expiration means less than when it was CELG's chief revenue driver.Yet, BMY trades at a real discount to other big healthcare stocks. For investors, the top and future cancer fighter offers a great long-term play at cheap prices.As of this writing, Aaron Levitt was long AMGN and ABMD. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post 5 Healthcare Stocks to Pick Up From the Wreckage appeared first on InvestorPlace.
- Simply Wall St.•17 days ago
Stryker Corporation (NYSE:SYK) Earns A Nice Return On Capital Employed
Today we'll look at Stryker Corporation (NYSE:SYK) and reflect on its potential as an investment. Specifically, we'll...
- Investopedia•22 days ago
The Top Health Care Companies in the World
An introduction to health care companies that are tops in their fields. From health care provider to pharmaceuticals, these companies have the largest global presence according to market capitalization. Learn who these health care giants are and why they may be a good investment.
- Zacks•27 days ago
Can Segmental Growth Aid Cooper Companies' (COO) Q2 Earnings?
Cooper (COO) expects to gain from CVI and CSI units in the fiscal second quarter.
- Zacks•28 days ago
Veeva Systems (VEEV) to Report Q1 Earnings: What's in Store?
Top-line growth and solid show by Subscription services and Professional services units are likely to aid Veeva Systems (VEEV) in Q1 earnings. However, rising expenses remains a dampener.
- Zacks•28 days ago
Stryker (SYK) Up 0.5% Since Last Earnings Report: Can It Continue?
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- MoneyShow•28 days ago
Argus Expert Eyes "Min Vol" Stocks for Defensive Investors
With the stock market stalled on concerns over a trade war between the U.S. and China, some investors are beginning to investigate end-of-rally strategies, suggests John Eade, an analyst with the independent research firm, Argus Research.
- Simply Wall St.•last month
Stryker Corporation (NYSE:SYK) Has Attractive Fundamentals
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Zacks•last month
Integra LifeSciences Rides on Product Launch, Faces Rivalry
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
- Zacks•last month
Medtronic to Acquire Titan Spine for Spine Portfolio Boost
According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.
- Zacks•last month
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
- Zacks•last month
Medtronic's (MDT) EV ICD Pilot Study Results Encourage
The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.
- Zacks•last month
Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y
Nevro's (NVRO) domestic and international revenues fall year over year in Q1.
- Zacks•last month
Here's Why You Should Invest in Illumina (ILMN) Stock Now
Illumina (ILMN) has been gaining investor confidence on robust performance.
- Zacks•last month
National Vision's (EYE) Q1 Earnings Beat, Margins Decline
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
- Zacks•last month
Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
- Zacks•last month
LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1
LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.
